Lapatinib is a dual tyrosine kinase inhibitor of EGFR and ErbB2/HER2 receptors [12] that is used in combination therapy of ErbB2/HER2-positive breast cancer patients with advanced or metastatic tumors [13]. This evidence concerns the gene EGFR and breast cancer.